Navigation Links
Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
Date:5/20/2010

RESEARCH TRIANGLE PARK, N.C., May 20 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Lawrence D. Stern, chairman and chief executive officer of Talecris, will present at the 2010 Citi Investment Research Global Health Care Conference at 11:30 a.m., Thursday, May 27, 2010, at the Hilton New York Hotel in New York, N.Y.

A live webcast of Talecris' presentation will be accessible through the investor relations section of the Talecris Web site, www.talecris.com/investor-relations.htm. A replay of the webcast will be available until June 10, 2010, and can be accessed at the same Web address.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis.  For more information, please visit: www.talecris.com.


'/>"/>
SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
9. Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
10. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New ... receive exclusive marketing and sales rights for all non-OEM Transonic products in Japan. As ... Japan, the new Nipro - Transonic JV is a natural next step to advance ...
(Date:1/21/2017)... 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... Company in North America 2016. ... based on the FDA approval of three innovative ... ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
(Date:1/19/2017)... PUNE, India , Jan. 19, 2017  Market Research Future ... The Global Market for Liquid Biopsy is growing rapidly and expected ... period. Market Highlights ... The Global Liquid Biopsy Market has been assessed as ... high growth figures and boom in the coming future. There has ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):